Literature DB >> 17907951

Effects of growth factors on the differentiation of murine ESC into type II pneumocytes.

Ali Samadikuchaksaraei1, Anne E Bishop.   

Abstract

We have previously shown that embryonic stem cells (ESC) can be directed to differentiate into alveolar type II cells by provision of a serum-free medium designed for in vitro maintenance of mature alveolar epithelial cells (small airway growth medium: SAGM), although the target cell yield was low. SAGM comprises a basal serum-free medium (SABM) plus a series of defined supplements. In order to try increase the proportion of pneumocytes in differentiated cultures, we aimed in this study to determine the effects on murine ESC of each of the individual growth factors in SAGM. In accordance with our previous reports, expression of surfactant protein C (SPC) and its mRNA was used to monitor differentiation of type II pneumocytes. Surprisingly, we found that addition of each factor separately to SABM decreased the expression of SPC mRNA when compared with the effect of SABM alone. Thus, it seems that the observed enhancement by SAGM of pneumocyte differentiation from murine ESC can, in fact, be attributed to the provision of a serum-free environment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17907951     DOI: 10.1089/clo.2006.0008

Source DB:  PubMed          Journal:  Cloning Stem Cells        ISSN: 1536-2302


  9 in total

1.  A rapid lung de-cellularization protocol supports embryonic stem cell differentiation in vitro and following implantation.

Authors:  Todd Jensen; Blair Roszell; Fan Zang; Eric Girard; Adam Matson; Roger Thrall; Diane M Jaworski; Cayla Hatton; Daniel J Weiss; Christine Finck
Journal:  Tissue Eng Part C Methods       Date:  2012-04-17       Impact factor: 3.056

2.  Design and development of tissue engineered lung: Progress and challenges.

Authors:  Joan E Nichols; Jean A Niles; Joaquin Cortiella
Journal:  Organogenesis       Date:  2009-04       Impact factor: 2.500

3.  Differentiation of mouse induced pluripotent stem cells into alveolar epithelial cells in vitro for use in vivo.

Authors:  Qiliang Zhou; Xulu Ye; Ruowen Sun; Yoshifumi Matsumoto; Masato Moriyama; Yoshiya Asano; Yoichi Ajioka; Yasuo Saijo
Journal:  Stem Cells Transl Med       Date:  2014-04-24       Impact factor: 6.940

4.  Efficient generation of functional CFTR-expressing airway epithelial cells from human pluripotent stem cells.

Authors:  Amy P Wong; Stephanie Chin; Sunny Xia; Jodi Garner; Christine E Bear; Janet Rossant
Journal:  Nat Protoc       Date:  2015-02-05       Impact factor: 13.491

5.  Efficient derivation of alveolar type II cells from embryonic stem cells for in vivo application.

Authors:  Blair Roszell; Mark J Mondrinos; Ariel Seaton; Donald M Simons; Sirma H Koutzaki; Guo-Hua Fong; Peter I Lelkes; Christine M Finck
Journal:  Tissue Eng Part A       Date:  2009-11       Impact factor: 3.845

Review 6.  Human embryonic stem cells and lung regeneration.

Authors:  A Varanou; C P Page; S L Minger
Journal:  Br J Pharmacol       Date:  2008-08-25       Impact factor: 8.739

7.  Gene expression changes with differentiation of cord blood stem cells to respiratory epithelial cells: a preliminary observation.

Authors:  Michael J Berger; Sharon R Minnerath; Sheryl D Adams; Barbara M Tigges; Stacey L Sprague; David H McKenna
Journal:  Stem Cell Res Ther       Date:  2011-04-13       Impact factor: 6.832

8.  Human Lung Spheroids as In Vitro Niches of Lung Progenitor Cells with Distinctive Paracrine and Plasticity Properties.

Authors:  Isotta Chimenti; Francesca Pagano; Francesco Angelini; Camilla Siciliano; Giorgio Mangino; Vittorio Picchio; Elena De Falco; Mariangela Peruzzi; Roberto Carnevale; Mohsen Ibrahim; Giuseppe Biondi-Zoccai; Elisa Messina; Giacomo Frati
Journal:  Stem Cells Transl Med       Date:  2016-09-22       Impact factor: 6.940

9.  Amnion epithelial cells as a candidate therapy for acute and chronic lung injury.

Authors:  Ryan J Hodges; Rebecca Lim; Graham Jenkin; Euan M Wallace
Journal:  Stem Cells Int       Date:  2012-04-11       Impact factor: 5.443

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.